Skip to main content

Day: August 6, 2025

First Quantum Minerals Announces Cash Tender Offer to Purchase Any and All of Its Outstanding 6.875% Senior Notes Due 2027

(In United States dollars, except where noted otherwise) TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (the “Company” or “First Quantum”) (TSX: FM) today announced that it has commenced an offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 6.875% Senior Notes due 2027 (the “Notes”) from holders of the Notes (“Holders”), as further described in the offer to purchase dated the date hereof (the “Offer to Purchase”) and the related Notice of Guaranteed Delivery. The Tender Offer will expire at 5:00 pm, New York City time, on August 12, 2025 (such date, as may be extended, the “Expiration Date”). The consideration for each $1,000 principal amount of Notes tendered prior to the Expiration Date and accepted for purchase pursuant to the Tender Offer shall be the “Notes Consideration”...

Continue reading

Kornit Digital Reports Second Quarter 2025 Results

Second quarter revenues of $49.8 million, in line with previous guidance Second quarter GAAP net loss of $7.5 million; non-GAAP net income of $1.2 million Continued to generate cash from operations Reported annual recurring revenue from AIC contracts of $18.9 million, reflecting continued adoption of this new model, particularly from screen-printing customers.ROSH-HA`AYIN, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production technologies, today reported results for the second quarter ended June 30, 2025. “We delivered second quarter results within our guidance range in a challenging market environment, reflecting ongoing progress in transforming our business toward recurring revenue and long-term...

Continue reading

Purple Biotech Reports Second Quarter 2025 Financial Results

Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with IND submission expected in 2026 Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025 NT219 Phase 2 study in head and neck cancer initiated in June 2025 REHOVOT, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today financial results...

Continue reading

Sprott Announces Second Quarter 2025 Results

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three and six months ended June 30, 2025. Management commentary “Sprott’s Assets Under Management (“AUM”) were $40 billion as at June 30, 2025, up 14% from $35.1 billion as at March 31, 2025 and up 27% from $31.5 billion as at December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “During the quarter we benefited from market value appreciation across our product suite, driven by rising precious metals and uranium prices and strong performance in our managed equities segment. We also reported $1.2 billion in net sales during the quarter, concentrated largely in our physical trusts.” “We are pleased with how our balanced product offerings...

Continue reading

Brink’s Delivers Strong Second-Quarter Results Exceeding Top End of Guidance for Revenue, Operating Profit, and EBITDA

Record Second-Quarter Operating Profit Margin as AMS/DRS Continue to Gain MomentumIncreasing Full-Year 2025 Revenue and EBITDA Expectations RICHMOND, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced second-quarter results. Mark Eubanks, president and CEO, said: “I am proud of our consistent execution and the delivery of another quarter of meaningful progress against our strategic priorities. We continue to grow higher-margin subscription-based AMS / DRS revenue, expand our profit margins, improve our cash conversion and return capital to shareholders. This was clear in our strong second quarter performance which exceeded the top end of our quarterly guidance for revenue,...

Continue reading

Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled, “Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection,” details studies showing robust and durable protection from lethal tularemia exposure in both rat and non-human primate models. ATI-1701,...

Continue reading

MiniLuxe Announces Best of Boston Award for Manicure and Pedicure Services

MiniLuxe wins the annual Boston Magazine, Best of Boston Award for Best Mani and Pedi Boston, MA, Aug. 06, 2025 (GLOBE NEWSWIRE) — MiniLuxe, a leader in clean beauty and self-care services, proudly announces receiving Best Manicure and Pedicure Services granted by Boston Magazine’s Best of Boston 2025. Meticulously researched by the magazine’s writers and editors who spend months testing and debating, Boston Magazine’s list of winners represents “Boston’s must-visit list this year.” MiniLuxe has won the award multiple times since its founding. “It is wonderful to gain local recognition from Boston Magazine. As MiniLuxe started in the greater Boston area, this award is very meaningful to us and is equally a testament to the quality and dedication of our nail designers and waxing specialists,” said Tony Tjan, CEO of MiniLuxe. The...

Continue reading

Vishay Intertechnology Reports Second Quarter 2025 Results

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal second quarter ended June 28, 2025. Highlights2Q 2025 revenues of $762.3 million Gross margin was 19.5% and included the negative impact of approximately 160 basis points related to the addition of Newport 2Q 2025 EPS of $0.01 2Q 2025 Adjusted loss per share of $(0.07) 2Q 2025 book-to-bill of 1.02 with book-to-bill of 0.98 for semiconductors and 1.06 for passive components Backlog at quarter end was 4.6 months“The promising signals we saw emerging at the beginning of the year contributed to a 7% sequential increase in revenue for the second quarter. We delivered growth for semis and passives,...

Continue reading

Vertex Announces Second Quarter 2025 Financial Results

KING OF PRUSSIA, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2025. “This quarter’s results were in line with expectations, with double-digit revenue growth and healthy profitability and cash flow,” said David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “We continue to be optimistic about the future for Vertex. As indirect taxes continue to grow in complexity, our customers need our solutions more than ever. In addition, ERP cloud conversions and the proliferation of e-invoicing mandates globally are expected to be durable long-term drivers of growth.” Second Quarter 2025 Financial ResultsTotal revenues of $184.6...

Continue reading

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v. YTD 2024 Advanced pipeline:Submitted sBLA for Afrezza® in pediatric population MNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of schedule MNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business update. “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In our orphan lung pipeline,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.